Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 févr. 2016 08h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
27 janv. 2016 08h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
14 janv. 2016 13h19 HE | Source: Societal CDMO, Inc.

Recro Pharma to Present at NobleCon12 Investor Conference

MALVERN, Pa., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
06 janv. 2016 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam

IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported Company on Track to Initiate Pivotal Phase III in 1Q 2016 MALVERN, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) --...
02 déc. 2015 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer

MALVERN, Pa., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
24 nov. 2015 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference

MALVERN, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
13 nov. 2015 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Reports Third Quarter 2015 Financial Results

MALVERN, Pa., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
12 nov. 2015 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
26 oct. 2015 08h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Provides Pipeline Update

IV Meloxicam Advancing to Phase III; Pivotal Trials Expected to Commence in First Quarter 2016 Company Shifts Focus of Dex-IN to Peri-Procedural Pain Indication MALVERN, Pa., Oct. 26, 2015...
10 sept. 2015 13h41 HE | Source: Societal CDMO, Inc.

Recro Pharma Appoints Karen A. Flynn to Its Board of Directors

MALVERN, Pa., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...

Page précédente